ホーム>>Signaling Pathways>> Proteases>> Mitochondrial Metabolism>>SH-BC-893

SH-BC-893

カタログ番号GC70569

SH-BC-893は経口活性抗腫瘍鞘脂類似体である。

Products are for research use only. Not for human use. We do not sell to patients.

SH-BC-893 化学構造

Cas No.: 1841409-92-4

サイズ 価格 在庫数 個数
1 mg
$522.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity.

SH-BC-893 starves cancer cells to death by down-regulating cell surface nutrient transporters and blocking lysosomal trafficking events[1].
SH-BC-893 (5 μM; 3 h) protects from ceramide-induced mitochondrial network fragmentation by disrupting intracellular trafficking[2].
SH-BC-893 (8.935 nM; 3 h) protects from ceramide-induced mitochondrial dysfunction[2].

SH-BC-893 (oral; 120 mg/kg; single) robustly and acutely blocks ceramide-induced mitochondrial dysfunction, correcting diet-induced obesity and its metabolic sequelae[1].

References:
[1]. Kubiniok, Peter et al. Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs. Molecular & cellular proteomics : MCP vol. 18,3 (2019): 408-422.
[2]. Jayashankar, Vaishali et al. Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity. EMBO molecular medicine vol. 13,8 (2021): e13086.

レビュー

Review for SH-BC-893

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SH-BC-893

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.